DPP4 and type 2 diabetes mellitus: Since GLP-1 and GIP augment glucose-induced insulin release from pancreatic b-cells, suppresses glucagon secretion, and slows gastric emptying [12,13], inhibition of DPP-4 has been proposed as a potential therapeutic target for the treatment of type 2 diabetes.